Mark S. Lesney, PhD December 20, 2021 The US Food and Drug Administration (FDA) has approved tezepelumab-ekko (Tezspire) as a first in class treatment for severe asthma in adults and pediatric patients aged 12 years and older. It is not recommended for the relief of acute bronchospasm or status asthmaticus. Tezepelumab-ekko is a human monoclonal antibody that acts as...